propranolol ER / Generic mfg. - LARVOL DELTA

Development of propranolol hydrochloride extended-release lipid matrix tablets for pediatric use. (PubMed, Int J Pharm) - "The selected formulations showed good manufacturability, uniformity, and sustained drug release. Overall, several lipid-based matrix formulations suitable for pediatric use were identified, providing a promising basis for the development of solid oral extended-release dosage forms for children."

Journal • Pediatrics

Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD) (clinicaltrials.gov) - P4 | N=59 | Terminated | Sponsor: University of California, San Francisco | Phase classification: P=N/A ➔ P4

Phase classification • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

SAT-316 - Graves' disease with thyrotoxic hypokalemic periodic paralysis, A rare reported association (ENDO 2026) - "She was treated with methimazole 20 mg twice daily, propranolol LA 60 mg daily, and one dose of hydrocortisone. This case underscores the importance of considering TPP in any acute hypokalemic paralysis regardless of sex and highlights the management pitfall of over aggressive potassium replacement: rebound hyperkalemia has been reported in a substantial minority of treated episodes. Rapid control of thyrotoxicosis with non selective beta blockade and antithyroid therapy is central to abort attacks and prevent recurrence."

Late-breaking abstract • Endocrine Disorders • Grave’s Disease

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular

Propranolol for Tremors in Spinocerebellar Ataxia Type 12: A Randomized Clinical Trial. (PubMed, Mov Disord) - "Propranolol effectively reduced tremors and improved quality of life in SCA12, with good tolerability."

Clinical • Journal • Ataxia • CNS Disorders • Essential Tremor • Fatigue • Movement Disorders • Pain • Parkinson's Disease

ENDOSCOPIC VARICEAL LIGATION ALONE OR IN COMBINATION WITH NON-SELECTIVE BETA BLOCKERS FOR SECONDARY PROPHYLAXIS IN CHILDREN WITH NON-CIRRHOTIC PORTAL HYPERTENSION- A RANDOMIZED CONTROL TRIAL (AASLD 2025) - "Patients in EVL+NSBB arm were started on long acting propranolol (1-3mg/kg/day) targeting a 25% reduction in heart rate... Addition of NSBB to EVL does not affect the rebleeding rate but reduces the recurrence or need for further endotherapy of EV in follow-up, maintains platelet count and downgrades GV in children with NCPH and EVB. NSBB are safe and well tolerated in children."

Clinical • Combination therapy • Cardiovascular • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Hypotension • Immunology • Portal Hypertension • Varicose Veins

Propranolol Mitigates Cardiovascular Effects of CPAP Withdrawal (ATS 2025) - " We performed a double-blind randomized crossover trial of propranolol (Inderal LA 80 mg, PRO) vs. placebo (PLA) in patients with OSA during 3-night CPAP withdrawal. 21 participants (51±11 years old, 62% male, BMI 33.8 ± 6.8 kg/m2) completed the study. As expected, CPAP withdrawal led to resumption of severe OSA (AHI 43 events/hr). PRO decreased mean overnight HR by 3.9 beats /min (p<0.001)."

Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Hypotension • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular

Thyroid Storm at Sea: A Case of Algae Induced Thyrotoxicosis (AACE 2024) - "She received intravenous Metoprolol for control of tachycardia, propylthiouracil (PTU), decadron, potassium iodine, and insulin infusion for DKA. PTU was changed to Methimazole and cholestyramine on day 2 due to worsening transaminitis. On day 5, she was transitioned to long acting Propranolol, Methimazole, and a tapered steroid course...Beta blockers with or without antithyroid drugs are the mainstay of treatment for iodine induced thyrotoxicosis. Healthcare providers should warn patients of the potential dangers of unregulated supplements, particularly about using iodine containing seaweed products which can be toxic to the thyroid even in small quantities."

Clinical • Cardiovascular • Critical care • Diabetes • Endocrine Disorders • Metabolic Disorders • Ophthalmology • Type 1 Diabetes Mellitus

A rare pesentation of Alirocumab-mediated acute interstitial nephritis (NKF-SCM 2024) - "His current medications included ramipril 5mg, rosuvastatin 40mg, propranolol ER 60mg, aspirin 81mg, and alirocumab.He had begun once a month alirocumab as part of a lipid lowering therapy regimen 4 months ago, and he had taken 3 doses in total...Renal biopsy revealed changes consistent with acute interstitial nephritis with negative staining for IgG4 presence.He received 2 sessions of hemodialysis.Aloricumab held.He was started on prednisone 60mg x 2 weeks followed by taper.All other causes of AIN were thoroughly excluded.Creatinine slowly trended down to 1.8... Alirocumab is an increasingly popular second-line medication prescribed for the treatment of hypercholesterolemia. While few side effects are well known, the potential renal side effects of the medication have not been well documented except ATN in form of a case report. To our knowledge, our case represents the first incidence of acute interstitial nephritis associated with alirocumab injection as shown by the..."

Cardiovascular • Coronary Artery Disease • Dyslipidemia • Fatigue • Hypertension • Metabolic Disorders • Nephrology • Vasculitis

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular

"Amen. And propranolol ER in particular." (,@jarenblake)

Teprotumumab Induced Type 1 Diabetes Mellitus (AACE 2023) - "Her levothyroxine was stopped by PCP and she was started on methimazole 10 mg tid and propranolol ER 60 mg daily...She was started on metformin XR 500 mg bid given her diagnosis of prediabetes and plan for Teprotumumab therapy. She achieved smoking cessation with varenicline...Subsequently methimazole was decreased to 2.5 mg daily and Metformin increased to 1g bid and addition of glimepiride 2mg daily...Further evaluation for this patient is still pending with initiation of insulin therapy. We hope that this case can help guide research, safety protocols, and awareness in the management of thyroid eye disease."

Diabetes • Endocrine Disorders • Metabolic Disorders • Nicotine Addiction • Ophthalmology • Thyroid Eye Disease • Tobacco Cessation • Type 1 Diabetes Mellitus

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cardiovascular

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Christiana Care Health Services | Recruiting ➔ Completed

Trial completion • Obstetrics

Long-term esthetic outcome of treatment with propranolol or atenolol for infantile hemangioma (ESPD 2022) - No abstract available.

Neurocognitive functioning, physical health, and mental health of school-aged children treated with propranolol or atenolol for infantile hemangioma (ESPD 2022) - "In children aged 6 months to <6 years with moderate-to-severe AD, dupilumab q4w+low-potency TCS rapidly and signifi-cantly improved AD signs and symptoms. Dupilumab was well toler-ated and demonstrated an acceptable safety profile."

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Christiana Care Health Services | N=200 ➔ 80

Enrollment change

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Christiana Care Health Services | Trial primary completion date: Jan 2022 ➔ Jun 2022

Trial primary completion date

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Vanderbilt University Medical Center; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Cardiovascular

BISP: Biopsychosocial Influence on Shoulder Pain (clinicaltrials.gov) - P2; N=264; Completed; Sponsor: Duke University; Recruiting ➔ Completed; N=448 ➔ 264

Enrollment change • Preclinical • Trial completion • Musculoskeletal Pain • Pain • IL1B • IL6 • TNFA

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - P2; N=10; Completed; Sponsor: Columbia University; Active, not recruiting ➔ Completed

Clinical • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1; N=200; Recruiting; Sponsor: Christiana Care Health Services; Not yet recruiting ➔ Recruiting

Enrollment open

Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD) (clinicaltrials.gov) - P=N/A; N=59; Terminated; Sponsor: University of California, San Francisco; N=110 ➔ 59

Enrollment change • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients (clinicaltrials.gov) - P2; N=25; Completed; Sponsor: Medical College of Wisconsin; Active, not recruiting ➔ Completed

Clinical • Trial completion • Bone Marrow Transplantation • Hematological Malignancies • Mood Disorders • Multiple Myeloma • Neutropenia • Oncology • Transplantation